Arcturus Therapeutics Hits 52-Week Low at $5.77 Amid Ongoing Decline

Arcturus Therapeutics Holdings, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 5.77 on July 20, 2026. This significant decline highlights the company's ongoing struggles, as it has experienced a staggering 81.28% drop in its stock price over the past year, contrasting sharply with the S&P 500's positive performance of 18.21% during the same period. The company's financial metrics reveal a challenging landscape, with a market capitalization of USD 192 million and a negative return on equity of -23.21%. Arcturus has reported negative results for six consecutive quarters, with net sales for the half-year plummeting by 92.06% to USD 3.69 million. Additionally, pre-tax profit has fallen dramatically, reflecting a decline of 112.31%. With a price-to-book ratio of 0.90, the stock is trading at a valuation that suggests significant risk compared to its historical performance. As Arcturus navigates these financial hurdles, its recent low underscores the ongoing volatility and challenges faced by the company in the competitive biotechnology landscape.